Jean-Frederic Colombel, MD, offers insights into subcutaneous infliximab-dyyb injection, detailing its administration and approved indications for ulcerative colitis and Crohn's disease.
Reducing Treatment Burden in IBD with At-Home Therapy Options
A key opinion leader analyzes the clinical remission and endoscopic response data from the LIBERTY CD and LIBERTY UC trials for subcutaneous infliximab-dyyb injection, contrasts it with intravenous infliximab, and evaluates the drug's safety and efficacy profile.
Jean-Frederic Colombel, MD, examines considerations for transitioning patients from intravenous to subcutaneous infliximab and evaluates the role of subcutaneous infliximab within the evolving landscape of inflammatory bowel disease treatments.
Advertisement
Advertisement
Trending on HCPLive
1
FDA Approves Olezarsen (Tryngolza) for Severe Hypertriglyceridemia
2
Delgocitinib Approval Fills a Long-Standing Gap in Chronic Hand Eczema Treatment
3
The Medical Sisterhood: The Strength Nobody Talks About, with Saakshi Khattri, MD
4
Q&A: Cardiometabolic Care Cascade Failure Points, with Rishi Wadhera, MD, MPP, MPhil
5